The following announcement was sent to the Fibromyalgia patient community by the Food and Drug Administration on September 25, 2013.
Dear Patient Stakeholder,
We invite you to attend an upcoming public meeting on fibromyalgia, as part of FDA’s Patient-Focused Drug Development initiative. The goal of the meeting is to hear patient perspectives on symptoms of fibromyalgia that matter most to patients and on current approaches to treating fibromyalgia.
Date: December 10, 2013
Time: 1:00 pm – 5:00 pm
Location: FDA White Oak campus at 10903 New Hampshire Avenue, Silver Spring, MD
Visit the FDA website for more information and to register for the meeting: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm363203.htm.
We’ve also developed a series of webinars to provide background on FDA and Patient-Focused Drug Development: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm349133.htm. Watching these webinars in advance may be helpful in preparing for the meeting.
The patient voice is integral to FDA’s Patient-Focused Drug Development initiative. We encourage you to reach out to your peers, patients, and other patient stakeholders to spread the word by forwarding on this email and sharing through social media.
We look forward to this exciting meeting and hope to see you there. If you have any questions, please feel free to contact Andrea Furia-Helms at
or Graham Thompson at